Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Dow
Johnson and Johnson
Merck
Express Scripts

Last Updated: August 13, 2022

Investigational Drug Information for ASP1517


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for ASP1517?

ASP1517 is an investigational drug.

There have been 24 clinical trials for ASP1517. The most recent clinical trial was a Phase 3 trial, which was initiated on September 3rd 2013.

The most common disease conditions in clinical trials are Anemia, Renal Insufficiency, Chronic, and Kidney Diseases. The leading clinical trial sponsors are FibroGen, Astellas Pharma Inc, and Astellas Pharma Europe B.V.

There are forty-four US patents protecting this investigational drug and three hundred and eighty-seven international patents.

Recent Clinical Trials for ASP1517
TitleSponsorPhase
A Study to Assess the Relative Bioavailability of Roxadustat Following a Single Dose of Pediatric Azo Dye-free Tablet Formulation and Pediatric Azo Dye-free Mini-tablet Formulation Compared to a Single Dose of Azo Dye-containing Tablet Formulation iFibroGenPhase 1
A Study to Assess the Relative Bioavailability of Roxadustat Following a Single Dose of Pediatric Azo Dye-free Tablet Formulation and Pediatric Azo Dye-free Mini-tablet Formulation Compared to a Single Dose of Azo Dye-containing Tablet Formulation iAstellas Pharma Global Development, Inc.Phase 1
Efficacy and Safety of FG-4592 for Treatment of Anemia in Patients With Lower Risk MDS With Low Red Blood Cell Transfusion BurdenAstellas Pharma IncPhase 3

See all ASP1517 clinical trials

Clinical Trial Summary for ASP1517

Top disease conditions for ASP1517
Top clinical trial sponsors for ASP1517

See all ASP1517 clinical trials

US Patents for ASP1517

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ASP1517 See Plans and Pricing Nitrogen-containing heteroaryl compounds and methods of use thereof FibroGen, Inc. (San Francisco, CA) See Plans and Pricing
ASP1517 See Plans and Pricing Crystalline forms of a prolyl hydroxylase inhibitor FibroGen, Inc. (San Francisco, CA) See Plans and Pricing
ASP1517 See Plans and Pricing Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) See Plans and Pricing
ASP1517 See Plans and Pricing Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN) See Plans and Pricing
ASP1517 See Plans and Pricing Generation of muscle lineage cells and therapeutic uses thereof GENEA BIOCELLS USA (HOLDINGS), INC. (San Diego, CA) See Plans and Pricing
ASP1517 See Plans and Pricing Crystalline forms of a prolyl hydroxylase inhibitor FibroGen, Inc. (San Francisco, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for ASP1517

Drugname Country Document Number Estimated Expiration Related US Patent
ASP1517 Austria AT496033 2023-06-06 See Plans and Pricing
ASP1517 Australia AU2004245552 2023-06-06 See Plans and Pricing
ASP1517 Brazil BRPI0411055 2023-06-06 See Plans and Pricing
ASP1517 Canada CA2528232 2023-06-06 See Plans and Pricing
ASP1517 China CN102718708 2023-06-06 See Plans and Pricing
ASP1517 China CN102977015 2023-06-06 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Dow
Johnson and Johnson
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.